Daewoong Pharmaceutical ayaa ku dhawaaqday natiijooyinka ugu sarreeya ee wejiga 3 ee tijaabada kiliinikada ee loogu talagalay daawaynta isku dhafka ah ee saddex-geesoodka ah ee Enavogliflozin, oo ah dawo cusub oo ka hortagga sonkorowga oo leh habka SGLT-2 inhibitor, oo leh Metformin iyo Gemigliptin. Enavogliflozin waa SGLT-2 ka hortagga sonkorowga ee horumarinta Daewoong markii ugu horeysay ee South Korea.

Borofisar Sungrae Kim oo ka tirsan Jaamacadda Katooliga ee Korea Bucheon St. Mary's Hospital oo ah isku-dubarid baadhe iyo baadhayaal maamule oo ka socda 27 machad ayaa ka qaybqaatay wajiga 3 tijaabada caafimaad ee Enavogliflozin sida daawaynta isku dhafka ah ee saddex-geesoodka ah ee Metformin iyo Gemigliptin. Daraasada waxaa loo sameeyay sidii xarun badan, randomized, laba-indho la'aan, iyo si firfircoon loo kantaroolo wajiga 3 tijaabo caafimaad oo ka kooban 270 bukaan oo qaba nooca 2 ee sonkorowga.

Bukaannada qaba nooca 2-aad ee sonkorowga, kuwaas oo la maamulay Metformin iyo Gemigliptin, ayaa sidoo kale la maamulay Enavogliflozin ama Dapagliflozin 24 toddobaad, iyo isbeddelka asaasiga ah ee haemoglobin glycated (HbA1c) ee u dhexeeya labada kooxood ee daraasadda ayaa la barbardhigay muddada daaweynta. Natiijo ahaan, bukaannada la maareeyay Enavogliflozin waxay muujiyeen hoos u dhac ku yimid heerka HbA1c 0.92% iyo 0.86% kuwa la maamulo Dapagliflozin, taasoo caddaynaysa hoos-u-dhac la'aanta Enavogliflozin marka la barbar dhigo Dapagliflozin.

Badbaadada Enavogliflozin ayaa sidoo kale lagu xaqiijiyay bukaanka qaba sonkorowga dhexdhexaadka ah, kuwaas oo u baahday daaweynta isku dhafka ah ee Metformin iyo Gemigliptin, maadaama aysan jirin falcelin daroogo oo lama filaan ah ama isdhexgalka daroogada. Badbaadada Enavogliflozin waxaa lagu caddeeyey seddex tijaabo oo isku xigta oo daaweyn ah oo monotherapy ah, isku darka metformin, iyo isku dhafka Metformin iyo Gemigliptin.

Baaraha isku xirka borofisar Kim wuxuu yiri, "Tijaabada kiliinikada ee Enavogliflozin's daawaynta isku dhafka ah ee seddexleyda ah marka la barbar dhigo Dapagliflozin oo ku saabsan 270 bukaan oo Kuuriyaan ah oo T2DM ah muddo 24 toddobaad ah ayaa caddaysay badbaadada iyo saameynta wanaagsan ee hoos u dhigista gulukooska dhiigga ee Enavogliflozin." "Waxaa la filayaa in Enavogliflozin uu noqdo ikhtiyaarka daawaynta ugu wanaagsan oo leh calaamad muujinaysa monotherapy iyo daaweynta isku dhafan," ayuu raaciyay.

Ka soo saarida natiijooyin macno leh wajiga 3 kiliinikada ee Enavogliflozin's daawaynta isku dhafka ah ee saddexlaha ah, Daewoong hadda waa tallaabo ku dhow sii deynta SGLT-2 cusub oo ah markii ugu horeysay ee Kuuriyada Koonfureed. Daewoong wuxuu qorsheynayaa inuu si dhakhso ah u codsado oggolaanshaha cusub ee dawada iyo inuu bilaabo kaliya Enavogliflozin laakiin sidoo kale Enavogliflozin/Metformin isku darka qiyaasta go'an ee daawada qeybtii hore ee 2023. Daewoong ayaa sii daayay natiijooyinka ugu sarreeya ee wajiga 3 tijaabada caafimaad ee Enavogliflozin monotherapy iyo Metformin daaweynta isku dhafka ah ee Janaayo.

MAXAA LAGU QAADAYAA MAQAALKAN:

Bringing out meaningful results from the phase 3 clinical trial of Enavogliflozin’s triple combination therapy, Daewoong is now a step closer to the release of a new SGLT-2 inhibitor for the first time in South Korea.
Daewoong Pharmaceutical announced the topline results of the phase 3 clinical trial for a triple combination therapy of Enavogliflozin, a new antidiabetic drug with the mechanism of SGLT-2 inhibitor, with Metformin and Gemigliptin.
Mary’s Hospital as a coordinating investigator and principal investigators from 27 institutions have participated in the phase 3 clinical trial for Enavogliflozin as a triple combination therapy with Metformin and Gemigliptin.